BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2009;18:1655-1666. [PMID: 19852566 DOI: 10.1517/13543780903241599] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Chen YF, Chong CL, Wu YC, Wang YL, Tsai KN, Kuo TM, Hong MH, Hu CP, Chen ML, Chou YC, Chang C. Doxorubicin Activates Hepatitis B Virus Replication by Elevation of p21 (Waf1/Cip1) and C/EBPα Expression. PLoS One 2015;10:e0131743. [PMID: 26121644 DOI: 10.1371/journal.pone.0131743] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
2 Zhang Q, Chen J, Pan M, Liu J, Liu T, Zhou Y. Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient. Virus Research 2018;255:165-70. [DOI: 10.1016/j.virusres.2018.07.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
3 Martin-carbonero L, Soriano V. New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. Journal of Antimicrobial Chemotherapy 2010;65:379-82. [DOI: 10.1093/jac/dkp492] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
4 Sampaio MS, Martin P, Bunnapradist S. Renal dysfunction in end-stage liver disease and post-liver transplant. Clin Liver Dis 2014;18:543-60. [PMID: 25017075 DOI: 10.1016/j.cld.2014.05.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
5 Bertacchi D, Zucca F, Foresti S, Mangioni D, Gori A. Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach. Math Med Biol 2015;32:383-403. [PMID: 25398978 DOI: 10.1093/imammb/dqu022] [Reference Citation Analysis]
6 Cox N, Tillmann H. Emerging pipeline drugs for hepatitis B infection. Expert Opin Emerg Drugs 2011;16:713-29. [PMID: 22195605 DOI: 10.1517/14728214.2011.646260] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
7 Huang R, Hao Y, Zhang J, Wu C. Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis. Hepatol Res 2013;43:1040-51. [PMID: 23356962 DOI: 10.1111/hepr.12058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
8 Eyer L, Nencka R, de Clercq E, Seley-Radtke K, Růžek D. Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses. Antivir Chem Chemother 2018;26:2040206618761299. [PMID: 29534608 DOI: 10.1177/2040206618761299] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 17.7] [Reference Citation Analysis]
9 Wang M, Yuan L, Qiao B, Li Y. Two rescue therapies in lamivudine-resistant patients with chronic hepatitis B in the central China: adefovir monotherapy and adefovir plus lamivudine. Virus Genes 2014;48:32-7. [PMID: 24203098 DOI: 10.1007/s11262-013-1004-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
10 Inoue T, Tanaka Y. Hepatitis B virus and its sexually transmitted infection - an update. Microb Cell 2016;3:420-37. [PMID: 28357379 DOI: 10.15698/mic2016.09.527] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
11 Mastroianni CM, Lichtner M, Citton R, Borgo CD, Rago A, Martini H, Cimino G, Vullo V. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011; 17(34): 3881-3887 [PMID: 22025876 DOI: 10.3748/wjg.v17.i34.3881] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
12 Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19(37): 6278-6283 [PMID: 24115827 DOI: 10.3748/wjg.v19.i37.6278] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
13 Sueki R, Maekawa S, Miura M, Kadokura M, Komase K, Shindo H, Kanayama A, Ohmori T, Shindo K, Amemiya F, Nakayama Y, Uetake T, Inoue T, Sakamoto M, Enomoto N. Correlation between pretreatment viral sequences and the emergence of lamivudine resistance in hepatitis B virus infection. J Med Virol 2012;84:1360-8. [PMID: 22825814 DOI: 10.1002/jmv.23314] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Chen XL, Li M, Zhang XL. HBV genotype B/C and response to lamivudine therapy: a systematic review. Biomed Res Int. 2013;2013:672614. [PMID: 24364035 DOI: 10.1155/2013/672614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
15 Somayaji MR, Das D, Garimella HT, German CL, Przekwas AJ, Simon L. An Integrated Biophysical Model for Predicting the Clinical Pharmacokinetics of Transdermally Delivered Compounds. Eur J Pharm Sci 2021;:105924. [PMID: 34289340 DOI: 10.1016/j.ejps.2021.105924] [Reference Citation Analysis]
16 Petersen J, Buti M. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Expert Rev Gastroenterol Hepatol. 2012;6:683-693; quiz 694. [PMID: 23237254 DOI: 10.1586/egh.12.52] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
17 Wang Z, Wu XL, Zeng WZ, Xu H, Zhang Y, Qin JP, Jiang MD. Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment. Virol J 2011;8:388. [PMID: 21816062 DOI: 10.1186/1743-422X-8-388] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
18 Reddy PN, Sampaio MS, Kuo HT, Martin P, Bunnapradist S. Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States. Clin J Am Soc Nephrol. 2011;6:1481-1487. [PMID: 21566110 DOI: 10.2215/cjn.09201010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
19 Jenh AM, Pham PA. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther. 2010;8:1079-1092. [PMID: 20954872 DOI: 10.1586/eri.10.91] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
20 Heuft MM, Houba SM, van den Berk GE, Smissaert van de Haere T, van Dam AP, Dijksman LM, Regez RM, Brinkman K. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection. AIDS 2014;28:999-1005. [DOI: 10.1097/qad.0000000000000180] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
21 Somayaji MR, Przekwas AJ, Gupta RK. Combination Therapy for Multi-Target Manipulation of Secondary Brain Injury Mechanisms. Curr Neuropharmacol 2018;16:484-504. [PMID: 28847295 DOI: 10.2174/1570159X15666170828165711] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
22 Shakya N, Vedi S, Liang C, Agrawal B, Tyrrell DL, Kumar R. A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses. Bioorg Med Chem Lett 2012;22:6475-80. [PMID: 22985854 DOI: 10.1016/j.bmcl.2012.08.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Aspinall EJ, Hawkins G, Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: a review. Occup Med (Lond). 2011;61:531-540. [PMID: 22114089 DOI: 10.1093/occmed/kqr136] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 7.7] [Reference Citation Analysis]
24 Jayakumar R, Joshi YK, Singh S. Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir. J Lab Physicians 2012;4:10-6. [PMID: 22923916 DOI: 10.4103/0974-2727.98664] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
25 Colombo GL, Gaeta GB, Viganò M, Di Matteo S. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res 2011;3:37-46. [PMID: 21935331 DOI: 10.2147/CEOR.S16655] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
26 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]